AU Patent

AU2004289083B2 — Use of glucosidase inhibitors for therapy of mucovisidosis

Assigned to Centre National de la Recherche Scientifique CNRS · Expires 2009-12-03 · 16y expired

What this patent protects

Glucosidase inhibitors are used to prepare medicaments for treating mucoviscidosis. ACTIVITY : CNS-Gen.; Respiratory-Gen. MECHANISM OF ACTION : Reactivator of cystic fibrosis transmembrane conductance regulator (CFTR) protein delF508 mutant. N-butyl deoxynojirimycin had an EC50 o…

USPTO Abstract

Glucosidase inhibitors are used to prepare medicaments for treating mucoviscidosis. ACTIVITY : CNS-Gen.; Respiratory-Gen. MECHANISM OF ACTION : Reactivator of cystic fibrosis transmembrane conductance regulator (CFTR) protein delF508 mutant. N-butyl deoxynojirimycin had an EC50 of 123 mu M for restoring iodide efflux in CF15 human lung epithelial cells (which are homozygotic for the delF508 mutation) after stimulation with forskoline and genisteine.

Drugs covered by this patent

Patent Metadata

Patent number
AU2004289083B2
Jurisdiction
AU
Classification
—
Expires
2009-12-03
Drug substance claim
No
Drug product claim
No
Assignee
Centre National de la Recherche Scientifique CNRS
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.